Celyad S.A. | Mutual Funds
Mutual Funds that own Celyad S.A.
Invesco Perpetual Sm. Cos. & Mkts Invt. Ser-European Sm. Cos.
134,784
1.12%
0
1.75%
03/29/2018
BNP Paribas B - Pension Balanced
83,199
0.7%
0
0.07%
09/29/2017
Carnegie Global Health Care Fund
69,446
0.57%
-2,153
1.13%
08/31/2018
Invesco Funds - Pan European Small Cap Equity Fund
68,431
0.56%
0
1.51%
03/29/2018
Invesco Perpetual European Invt. Ser. - European Opportunities
62,424
0.52%
0
1.89%
03/29/2018
Argenta Fonds d'Epargne Pension
55,023
0.46%
55,023
0.12%
12/31/2016
AXA Framlington Biotech Fund
45,200
0.38%
45,200
0.19%
02/28/2018
DFA Continental Small Company Series
42,198
0.35%
1,118
0.02%
01/31/2018
LBPAM Actions Santé
23,050
0.19%
0
0.46%
06/29/2018
16,100
0.14%
0
0.47%
07/31/2018
| Address |
Axis Business Park
Mont-Saint-Guibert WA 1435
Belgium
|
|
Employees
|
- |
| Website |
http://www.celyad.com |
| Updated |
07/08/2019 |
| Celyad SA is a clinical-stage biopharmaceutical company, which engages in the identification and development of specialized cell-based therapies. Its products include cardiopoiesis platform, immuno-oncology, and medical devices. The company was founded by Michel Lussier and William Wijns on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium. |
